Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
NOTV, BFRI and CPOP Among Pre-market Losers
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Barclays Sticks to Its Sell Rating for Allakos (ALLK)
Allakos Buy Rating: Clinical Promise and Financial Stability Drive Positive Outlook
Allakos | 10-Q: Quarterly report
Express News | Allakos Q1 2024 GAAP EPS $(0.81) Misses $(0.44) Estimate
Express News | Allakos - Continues to Expect to End 2024 With Total Cash, Cash Equivalents and Investments in Range of $81 to $86 Mln
Express News | Allakos Inc - Reiterates Restructuring Activities Will Extend Cash Runway Into Mid-2026
Express News | Allakos Q1 Operating Income USD -73.069 Million
Express News | Allakos Q1 Net Income USD -71.146 Million
Press Release: Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology com
Allakos 1Q Loss/Shr 81c >ALLK
Allakos 1Q Loss/Shr 81c >ALLK
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)